Maurus, Isabel http://orcid.org/0000-0002-6208-5180
Hasan, Alkomiet
Schmitt, Andrea
Roeh, Astrid
Keeser, Daniel
Malchow, Berend
Schneider-Axmann, Thomas
Hellmich, Martin
Schmied, Sabine
Lembeck, Moritz
Keller-Varady, Katriona
Papazova, Irina
Hirjak, Dusan
Topor, Cristina E.
Walter, Henrik
Mohnke, Sebastian
Vogel, Bob O.
Wölwer, Wolfgang
Schneider, Frank
Henkel, Karsten
Meyer-Lindenberg, Andreas
Falkai, Peter
Clinical trials referenced in this document:
Documents that mention this clinical trial
Aerobic endurance training to improve cognition and enhance recovery in schizophrenia: design and methodology of a multicenter randomized controlled trial
https://doi.org/10.1007/s00406-020-01175-2
Documents that mention this clinical trial
Aerobic endurance training to improve cognition and enhance recovery in schizophrenia: design and methodology of a multicenter randomized controlled trial
https://doi.org/10.1007/s00406-020-01175-2
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01EE1407E)
Article History
Received: 17 December 2019
Accepted: 22 July 2020
First Online: 3 August 2020
Change Date: 5 July 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00406-021-01289-1
Compliance with ethical standards
:
: AH is co-editor of the German (DGPPN) schizophrenia treatment guidelines and first author of the WFSBP schizophrenia treatment guidelines; he has been on the advisory boards and has received speaker fees from Janssen-Cilag, Lundbeck, and Otsuka. AS was an honorary speaker for TAD Pharma and Roche and a member of Roche advisory boards. PF is a co-editor of the German (DGPPN) schizophrenia treatment guidelines and a co-author of the WFSBP schizophrenia treatment guidelines; he is on the advisory boards and receives speaker fees from Janssen, Lundbeck, Otsuka, Servier, and Richter. AML has received consultant fees from Boehringer Ingelheim, Elsevier, Brainsway, Lundbeck Int. Neuroscience Foundation, Lundbeck A/S, Sumitomo Dainippon Pharma Co., Academic Medical Center of the University of Amsterdam, Synapsis Foundation-Alzheimer Research Switzerland, IBS Center for Synaptic Brain Dysfunction, Blueprint Partnership, University of Cambridge, Dt. Zentrum für Neurodegenerative Erkrankungen, Zürich University, Brain Mind Institute, L.E.K. Consulting, ICARE Schizophrenia, Science Advances, Fondation FondaMental, v Behring Röntgen Stiftung, The Wolfson Foundation, and Sage Therapeutics; Additionally, he has received speaker fees from Lundbeck International Foundation, Paul-Martini-Stiftung, Lilly Deutschland, Atheneum, Fama Public Relations, Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Janssen-Cilag, Hertie Stiftung, Bodelschwingh-Klinik, Pfizer, Atheneum, University of Freiburg, Schizophrenia Academy, Hong Kong Society of Biological Psychiatry, Fama Public Relations, Spanish Society of Psychiatry, Italian Society of Biological Psychiatry, Reunions I Ciencia S.L., and Brain Center Rudolf Magnus UMC Utrecht, as well as the Prix Roger de Spoelberch grant and the CINP Lilly Neuroscience Clinical Research Award 2016. IM, ML, IP, AR, DK, CT, DH, SM, BV, WW, TSA, FS, KH, KK, SS, MH, BM, and HW report no conflicts of interest.
: oThis manuscript does not include any individual patient data .
: The clinical trial was approved by the local ethics committees. It was registered on the U.S. Department of Health`s website, a database of clinical trials conducted worldwide (NCT number: NCT03466112), and on the German Clinical Trials Register (DRKS-ID: DRKS00009804).